                         SEQUENCE LISTING

<110>  Boehringer Ingelheim International GmbH
 
<120>  Epigenetic Engineering

<130>  P01-2522

<160>  11    

<170>  PatentIn version 3.3

<210>  1
<211>  47
<212>  DNA
<213>  Artificial

<220>
<223>  shRNA TIP5-1

<400>  1
ggacgataaa gcaaagatgt tcaagagaca tctttgcttt atcgtcc                   47


<210>  2
<211>  47
<212>  DNA
<213>  Artificial

<220>
<223>  shRNA TIP5-2

<400>  2
gcagcccagg gaaactagat tcaagagatc tagtttccct gggctgc                   47


<210>  3
<211>  60
<212>  DNA
<213>  Artificial

<220>
<223>  miRNA TIP5-1

<400>  3
gatcagccgc aaactcctct gagttttggc cactgactga ctcagaggat tgcggctgat     60


<210>  4
<211>  60
<212>  DNA
<213>  Artificial

<220>
<223>  miRNA TIP5-2

<400>  4
gcaaagatgg gatcagttaa gggttttggc cactgactga cccttaactt cccatctttg     60


<210>  5
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  Primer -168/-149 forward

<400>  5
gaccagttgt tgctttgatg                                                 20


<210>  6
<211>  20
<212>  DNA
<213>  Artificial

<220>
<223>  Primer -10/+10 reverse

<400>  6
gcgtgtcagt acctatctgc                                                 20


<210>  7
<211>  19
<212>  DNA
<213>  Artificial

<220>
<223>  Primer -100/-84 forward

<400>  7
tcccgacttc cagaatttc                                                  19


<210>  8
<211>  47
<212>  RNA
<213>  Artificial

<220>
<223>  shRNA TIP5-1.1

<400>  8
ggacgauaaa gcaaagaugu ucaagagaca ucuuugcuuu aucgucc                   47


<210>  9
<211>  47
<212>  RNA
<213>  Artificial

<220>
<223>  shRNA TIP5-2.1

<400>  9
gcagcccagg gaaacuagau ucaagagauc uaguuucccu gggcugc                   47


<210>  10
<211>  60
<212>  RNA
<213>  Artificial

<220>
<223>  miRNA TIP5-1.1

<400>  10
gaucagccgc aaacuccucu gaguuuuggc cacugacuga cucagaggau ugcggcugau     60


<210>  11
<211>  60
<212>  RNA
<213>  Artificial

<220>
<223>  miRNA TIP5-2.1

<400>  11
gcaaagaugg gaucaguuaa ggguuuuggc cacugacuga cccuuaacuu cccaucuuug     60


